Shareholders of Cytokinetics, Incorporated should get in touch with Levi & Korsinsky prior to November 17, 2025 to discuss legal options concerning CYTK shares
In a significant development, Cytokinetics, Inc. is the subject of a class action securities lawsuit. The lawsuit, filed by an unnamed lead plaintiff before November 17, 2025, alleges securities fraud related to the timeline for the New Drug Application ("NDA") submission and approval process for aficamten.
The lawsuit seeks to recover losses for investors in Cytokinetics who were adversely affected between December 27, 2023, and May 6, 2025. The defendants, according to the lawsuit, were aware of potential REMS requirements but chose to omit this information from the initial submission.
The revelation of the truth about the regulatory timeline has resulted in significant losses for class members. Defendants represented that the Company expected FDA approval for its NDA for aficamten in the second half of 2025, but failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS"). On May 6, 2025, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation, but chose to submit the NDA without a REMS.
Investors who suffered a loss in Cytokinetics during the specified time frame have until November 17, 2025, to request appointment as lead plaintiff. Class members can get more information and be contacted by a member of Levi & Korsinsky, LLP by following the link: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=168135&wire=3
Levi & Korsinsky, LLP, a renowned law firm with over 70 employees, has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years. The firm has a track record of winning high-stakes cases and extensive expertise in complex securities litigation. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Investors can participate in the potential recovery without serving as a lead plaintiff. They can contact Joseph E. Levi, Esq., Managing Partner of Levi & Korsinsky, LLP, via email at [email protected] or by telephone at (212) 363-7500. The firm's contact information is as follows:
Levi & Korsinsky, LLP 33 Whitehall Street New York, NY 10004 Tel: (212) 363-7500 Fax: (212) 363-7171 Website: www.zlk.com
There are no out-of-pocket costs or fees for class members seeking compensation. Participation in the lawsuit does not require serving as a lead plaintiff. Investors are encouraged to contact Levi & Korsinsky, LLP to discuss their rights and potential remedies.
Read also:
- A Business Model Explained: Its Purpose and Benefits for Your Venture
- Trump administration faces lawsuit by Denmark's Ørsted over halted wind farm project
- U.S. takes a pledge of $75 million to foster Ukrainian resources development
- Deep-rooted reinforcement of Walkerhughes' acquisitions through strategic appointment of Alison Heitzman
